JP2008509936A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509936A5
JP2008509936A5 JP2007526120A JP2007526120A JP2008509936A5 JP 2008509936 A5 JP2008509936 A5 JP 2008509936A5 JP 2007526120 A JP2007526120 A JP 2007526120A JP 2007526120 A JP2007526120 A JP 2007526120A JP 2008509936 A5 JP2008509936 A5 JP 2008509936A5
Authority
JP
Japan
Prior art keywords
vaccine
dose level
antigen
spp
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007526120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509936A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2005/001229 external-priority patent/WO2006017894A1/en
Publication of JP2008509936A publication Critical patent/JP2008509936A/ja
Publication of JP2008509936A5 publication Critical patent/JP2008509936A5/ja
Pending legal-status Critical Current

Links

JP2007526120A 2004-08-17 2005-08-17 経口不活化ワクチンのための用量を決定するための方法 Pending JP2008509936A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004904671A AU2004904671A0 (en) 2004-08-17 Method for determining dosage for an oral killed vaccine
PCT/AU2005/001229 WO2006017894A1 (en) 2004-08-17 2005-08-17 Method for determining dosage for an oral killed vaccine

Publications (2)

Publication Number Publication Date
JP2008509936A JP2008509936A (ja) 2008-04-03
JP2008509936A5 true JP2008509936A5 (https=) 2008-07-10

Family

ID=35907168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007526120A Pending JP2008509936A (ja) 2004-08-17 2005-08-17 経口不活化ワクチンのための用量を決定するための方法

Country Status (6)

Country Link
US (1) US20070269376A1 (https=)
EP (1) EP1793848A4 (https=)
JP (1) JP2008509936A (https=)
CN (1) CN101060858A (https=)
CA (1) CA2578189A1 (https=)
WO (1) WO2006017894A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109958A1 (en) * 2007-03-15 2008-09-18 Hunter Immunology Limited Methods for evaluation of oral vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778750A (en) * 1986-02-19 1988-10-18 Imreg, Inc. Diagnostic methods for immune function
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
US8758759B2 (en) * 2002-10-17 2014-06-24 Enzo Biochem, Inc. Transmucosal administration of aggregated antigens

Similar Documents

Publication Publication Date Title
Freidag et al. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis
Goodnow Biology of Bordetella bronchiseptica
Harro et al. Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration
Friedman et al. Legionella pneumophila pathogenesis and immunity
JP2012153706A (ja) 粘膜感染症の処置のための組成物および方法
Kenney et al. Induction of protective immunity against lethal anthrax challenge with a patch
Zhan et al. Differential induction of macrophage-derived cytokines by live and dead intracellular bacteria in vitro
Asokanathan et al. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis
Li et al. A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines
Olafsdottir et al. IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
Capozzo et al. Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers
Geurtsen et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice
JP2003533489A5 (https=)
González-González et al. The protoxin Cry1Ac of Bacillus thuringiensis improves the protection conferred by intranasal immunization with Brucella abortus RB51 in a mouse model
Jiang et al. Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective
JP2019513722A (ja) 変異ボルデテラ菌株および使用方法
Barluzzi et al. Establishment of protective immunity against cerebral cryptococcosis by means of an avirulent, non melanogenic Cryptococcus neoformans strain
JP2008509936A5 (https=)
Homayoon et al. Pasteurella multocida inactivated with ferric chloride and adjuvanted with bacterial DNA is a potent and efficacious vaccine in Balb/c mice
Card et al. Modulation of allergic airway inflammation by the oral pathogen Porphyromonas gingivalis
Biet et al. Recombinant Mycobacterium bovis BCG producing IL‐18 reduces IL‐5 production and bronchoalveolar eosinophilia induced by an allergic reaction
CN108220183A (zh) 一株马流产沙门氏菌菌株smxj-97及其在马流产沙门氏菌疫苗中的应用
Sosroseno et al. l‐arginine‐dependent nitric oxide production of a murine macrophage‐like RAW 264.7 cell line stimulated with Porphyromonas gingivalis lipopolysaccharide
WO2009008912A3 (en) Mycobacterial mutants inducing il-12
Jordan et al. Modulation of the humoral immune response of swine and mice mediated by toxigenic Pasteurella multocida